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Abstract 
Purpose: To assess the associations of baseline and long-term GGT activity with risk of heart failure 
(HF), ventricular arrhythmias (VAs) and atrial fibrillation (AF). 
Methods: GGT measurements were made in a prospective cohort of 1,780 men free of HF and cardiac 
arrhythmias at baseline. Correction for within-person variability was made using data from repeat 
measurements taken several years apart.  
Results: During an average follow-up of 22 years, 222 HFs, 56 VAs, and 336 AFs events occurred. The 
regression dilution ratio of loge GGT was 0.68 [95% confidence interval (CI): 0.61-0.74]. Serum GGT was 
log-linearly associated with risk of HF, VAs, and AF. In analyses adjusted for established risk factors, the 
hazard ratios (HRs) (95% CIs) for HF, VAs, and AF per 1 standard deviation (SD) higher baseline loge 
GGT values were 1.25 (1.07-1.45), 1.37 (1.04-1.80), and 1.04 (0.92-1.18) respectively. After correction 
for within-person variability, the corresponding HRs were 1.38 (1.11-1.73), 1.58 (1.06-2.37), and 1.06 
(0.88-1.27). These findings remained consistent in analyses accounting for incident coronary heart disease 
and the development of impaired renal function. In a meta-analysis of five population-based studies, the 
fully-adjusted relative risks for HF per 1 SD higher baseline and long-term GGT values were 1.28 (1.20 to 
1.35) and 1.43 (1.31-1.56) respectively. In pooled analysis of two studies, the corresponding risks for AF 
were1.09 (1.02-1.16) and 1.14 (1.03-1.25) respectively. 
Conclusion: GGT is positively and log-linearly associated with future risk of HF, VAs, and AF. Further 
research is needed to assess the causal relevance of these findings. 
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Introduction 
Gamma-glutamyltransferase (GGT) activity has routinely been used in clinical practice to help indicate 
potential hepatic or biliary disease.1 Elevated GGT values may also reflect accumulation of hepatic fat,2 
oxidative stress,3 and have been shown to be associated with cardiovascular disease (CVD) outcomes. 
Several prospective studies have consistently demonstrated associations between GGT and risk of 
coronary heart disease (CHD),4 stroke,4 CVD mortality,5 and composite CVD events.4, 6 However, 
uncertainty persists regarding the association of GGT with HF and cardiac arrhythmias [(ventricular 
arrhythmias (VAs) and atrial fibrillation (AF)]. Heart failure is associated with unacceptably high 
morbidity and mortality risks7 and imposes a significant economic burden on health systems. Cardiac 
rhythm disturbances, with AF being the most commonly diagnosed arrhythmia in clinical practice, are 
considered to be the final events in a chain of complications leading to stroke and increased overall 
mortality.8 Cardiac arrhythmias and HF often coexist and share many common risk factors such as older 
age, hypertension, myocardial infarction, and diabetes.9 Both VAs and AF are associated with an 
increased risk of HF events and vice versa, with death being a common consequence.10 Though a number 
of population-based prospective studies have shown a positive association between baseline GGT activity 
and risk of HF events,5, 11, 12 no study has at yet assessed the long-term relevance of GGT activity to HF. 
There is very little information about the extent to which GGT fluctuates within individuals, as these data 
enhances the interpretation of epidemiological studies with an aetiological motivation. We have recently 
shown that GGT exhibits high within-person variability,13 which could be the result of measurement errors 
in assays, fluctuations due to acute phase reactions, lifestyle changes, ageing, and chronic disease. 
Therefore, analysis using only baseline measurements of GGT could underestimate the true strength of 
any aetiological association between GGT and disease outcome (i.e. “regression dilution bias”14). Previous 
studies may have considerably under-estimated the association between GGT and HF, therefore a need to 
estimate and correct for the effect of this regression dilution bias. Prospective data regarding the 
association between GGT and AF are sparse; Alonso and colleagues in the Atherosclerosis Risk in 
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Communities Study (ARIC) reported an association between GGT activity and an increased risk of AF.15 
To our knowledge, the prospective association between GGT and risk of VAs has however not been 
previously investigated.  
Against this background, we aimed to quantify more reliably than previously possible, the associations 
of GGT with risk of HF, VAs, and AF in a population-based cohort of 1,780 apparently healthy men from 
eastern Finland. To put our results into context, we also performed pooled analyses of available published 
prospective evidence on the associations.  
 
Methods 
Details of study population, endpoint ascertainment, risk factor assessment, statistical analyses, and 
literature search strategy can be found in Supplementary Materials 1 and 2. 
 
Results 
Baseline characteristics and correlates of gamma-glutamyltransferase 
Table 1 summarizes baseline characteristics of the 1,780 participants in the KIHD study. The mean age of 
the participants was 53 (SD 5) years. Median (interquartile range) GGT value was 20 (15-32) U/L. During 
an average follow-up of 22 years, there were 222 HF events (annual rate 5.67/1,000 person-years at risk; 
95% CI: 4.97 to 6.47); 56 incident VAs (annual rate 1.42/1,000 person-years at risk; 95% CI: 1.09 to 
1.84); and 336 incident AF events (annual rate 8.93/1,000 person-years at risk; 95% CI: 8.03 to 9.94). 
Serum GGT values were weakly to moderately and positively correlated with physical measures (BMI, 
blood pressure, and resting heart rate) and with several lipid, metabolic, and inflammatory markers. Weak 
inverse correlations were observed for age (r = -0.03) and HDL-C (r = -0.04). Baseline GGT values were 
higher in men with diabetes compared with men without diabetes, higher in men with a history of 
hypertension compared with men without a history of hypertension, and higher in current smokers 
compared with non-smokers. 
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Correction for within-person variability  
Repeat measurements of GGT taken 4 years and 11 years after baseline were available in a random sample 
of 624 men, yielding a total of 1,143 repeat measurements of GGT. Overall, the regression dilution ratio 
(RDR) of loge GGT, adjusted for age, was 0.68 (95% CI: 0.61to 0.74), suggesting that the associations 
using one-off or baseline measurements of GGT with the outcomes could be under-estimated by [(1/0.68)-
1]*100 = 47%.  
 
GGT and risk of heart failure 
Prospective cohort analysis  
In analyses adjusted for conventional risk factors (age, BMI, SBP, prevalent coronary heart disease, 
smoking status, history of diabetes mellitus, LVH, use of antihypertensive agents and lipid-lowering 
drugs), there was a log-linear association between GGT and HF risk (Figure 1; Supplementary 
Materials 3 and 4). The age-adjusted HR per 1 SD change in loge GGT value was 1.45 (95% CI: 1.28 to 
1.67; P < 0.001), which was somewhat attenuated following further adjustment for established risk factors 
1.25 (95% CI: 1.07 to 1.45; P = 0.004). After correction for within-person variability in GGT values, the 
similarly adjusted HRs were 1.74 (95% CI: 1.43 to 2.12; P < 0.001) and 1.38 (95% CI: 1.11 to 1.73; P = 
0.004) respectively. The results remained consistent on further adjustment for alcohol consumption, 
resting heart rate, triglycerides, total cholesterol, HDL-C, eGFR, and CRP and remained unchanged after 
further adjusting for incident CHD events during follow-up (253 cases) (Table 2). In adjustment for the 
development of impaired renal function during follow-up (172 cases), the results remained similar 1.23 
(95% CI: 1.05 to 1.44; P = 0.011) and 1.36 (95% CI: 1.07 to 1.72; P = 0.011) per 1 SD higher baseline and 
usual loge GGT values respectively. The total number of deaths that occurred during follow-up was 814, 
of which 365 were CVD deaths. In analyses including death as a competing risk event, the HRs were 0.96 
(95% CI: 0.74 to 1.25; P = 0.769) and 0.94 (95% CI: 0.64 to 1.38; P = 0.769) per 1 SD change in baseline 
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and usual loge GGT values respectively. HRs did not vary importantly by levels or categories of pre-
specified conventional risk factors (P for interaction > 0.05 for each) (Supplementary Material 5), and 
the main results remained similar in analyses that excluded the first five years of follow-up, participants 
with GGT values greater than three times the upper limit of normal, and participants with potential fatty 
liver disease (Data not shown). In subsidiary analyses, we found significant evidence of associations of 
GGT with CVD mortality and nonfatal HF (Supplementary Materials 6 and 7). 
 
Literature-based meta-analysis  
Including the current study, we identified five population-based prospective studies5, 11, 12, 16 reporting on 
the association between GGT and HF risk (Supplementary Materials 8 and 9). In a pooled analysis of 
210,841 participants and 1,821 HF events, the RRs for HF per 1 SD higher  baseline and usual GGT 
values, typically adjusted for several conventional and emerging risk factors were 1.28 (95% CI: 1.20 to 
1.35; P < 0.001) and 1.43 (95% CI: 1.31 to 1.56; P < 0.001) respectively (Figure 2). The summary RR 
was identical when a fixed effect model was employed. Exclusion of any single study at a time from the 
pooled analysis had minimal effect on the pooled RR. We found no evidence of heterogeneity among the 
contributing studies (I2=0%; P=0.791).  
 
Association of GGT with risk of cardiac arrhythmias 
In analyses adjusted for conventional risk factors, there was an approximately log-linear association 
between GGT and VAs (Figure 1; Supplementary Materials 3 and 4). The age-adjusted HR for VAs per 
1 SD change in baseline loge GGT value was 1.48 (95% CI: 1.16 to 1.90; P = 0.002), which was 
minimally attenuated following further adjustment for established risk factors 1.37 (95% CI: 1.04 to 1.80; 
P = 0.026). Similarly adjusted HRs per 1 SD change in usual loge GGT values were1.78 (95% CI: 1.24 to 
2.56; P = 0.002) and 1.58 (95% CI: 1.06 to 2.37; P = 0.026) respectively. The results were somewhat 
attenuated on further adjustment for alcohol consumption, resting heart rate, triglycerides, total 
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cholesterol, HDL-C, and eGFR and remained consistent on further adjustment for CRP and accounting for 
incident coronary events (Table 2). Hazard ratios did not vary importantly by levels or categories of pre-
specified conventional risk factors (P for interaction > 0.10 for each) (Supplementary Material 10). 
Whereas, there was a log-linear positive association of GGT with AF risk in analyses initially adjusted for 
age, the association was less robust on further adjustment for conventional risk factors (Figure 1; 
Supplementary Materials 3 and 4; Table 2). In pooled analysis of the KIHD and ARIC studies (11,113 
participants and 1,357 AF cases), the fully adjusted HRs for AF per 1 SD higher baseline and usual GGT 
values were 1.09 (95% CI: 1.02 to 1.16; P = 0.008) and 1.14 (95% CI: 1.03 to 1.25; P = 0.008). 
 
Discussion 
In addition to assessing the shape and magnitude of the prospective associations of baseline GGT activity 
with HF and AF, our study is the first to evaluate these aspects of the association of GGT with risk of 
VAs. By correcting for regression dilution using repeat measurement of GGT, we have also shown that 
these associations are considerably under-estimated (by approximately half) when baseline measurements 
of GGT are used. In this population of middle-aged men without HF and history of cardiac arrhythmias at 
baseline, whereas GGT was positively and log-linearly associated with risk of HF and VAs in analyses 
adjusted for several conventional risk factors; the initial positive log-linear association of GGT with risk of 
AF in age-adjusted analysis was somewhat attenuated on further adjustment for conventional risk factors. 
Alonso and colleagues in the ARIC study have also demonstrated a linear relationship to the association 
between GGT and AF, but their association remained independent of several potential confounders 
including incident coronary artery disease events as a time-dependent covariate.15 However, in our pooled 
analysis of the two studies, there was a statistically significant association between GGT and AF.  
Our findings remained consistent across several subgroups and levels of cardiovascular risk markers, 
and were unchanged in analyses that adjusted for CHD and impaired renal function during follow-up and 
in several sensitivity analyses. Pooled findings from the meta-analysis of five studies reinforces the 
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validity and generalizability of the GGT-HF association, suggesting that a two fold increase in usual GGT 
values is associated with approximately 40% higher risk of HF. However, given the high mortality rate in 
our study cohort which might have hindered our event of interest, the association between GGT and HF 
was attenuated when death was adjusted for as a competing risk event. This was not a surprising finding, 
as total deaths in the cohort included CVD mortality events and our subsidiary analysis demonstrated GGT 
to be associated with CVD mortality.  
 
Possible explanations for findings 
Proposed mechanistic pathways underpinning the associations of elevated GGT values and increased risk 
of HF and cardiac arrhythmias, include the pro-oxidant and pro-inflammatory activities17 of GGT and its 
direct involvement in atheromatous plaque formation.18 Other pathways implicated include underlying 
fatty liver,17 which is associated with low-grade inflammation, insulin resistance, and oxidative stress,19, 20 
- all known to be associated with increased risk of these cardiovascular outcomes.21-23 Endothelial 
dysfunction and exposure to environmental pollutants have also been postulated.24, 25 Given that CHD is a 
major cause of HF26 and the consistent observational association demonstrated between GGT and CHD,27 
underlying CHD may be mediating the association between GGT and HF. However, our association 
between GGT and HF remained persistent on accounting for incident CHD during follow-up. There is also 
a possibility that the association between GGT and HF may be due to reverse causation, as GGT is 
frequently increased in HF due to liver dysfunction commonly encountered in HF.28 However, this is 
unlikely given (i) that our analysis was pre-specified to include participants without a history of HF at 
baseline; (ii) the mean follow-up period (> 20 years) was sufficiently long to ascertain the risk for HF; and 
(iii) the findings remained robust on excluding the first five years of follow-up. In addition, given that 
GGT is also synthesized by the kidneys, there is a close relationship with renal function; therefore the 
association of GGT with HF may also reflect impaired renal function.29  Our findings, however, remained 
largely unchanged after adjusting for baseline renal function and accounting for the development of 
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impaired renal function. The robust linear and independent relationships demonstrated are suggestive of 
causality, but these require confirmation in robust randomized controlled trials. There are several 
pharmacological agents (e.g. insulin sensitizers and antioxidants) that modify levels of GGT, however, 
they also alter levels of other liver enzymes and lipid factors.30 In the absence of clinical trials however, 
Mendelian randomisation (MR) studies of genetic variants specifically related to GGT levels may provide 
another route to assess causality.31  
 
Implications of findings 
Our findings are relevant and may have clinical implications. It further extends the evidence base and thus 
highlights a clear link between serum GGT and the development of cardiovascular outcomes. The findings 
underscore a potentially deleterious role of increasing GGT activity on future risk of a wide range of 
adverse cardiovascular outcomes in the general population. Given that assays for GGT are sensitive, well 
standardised, simple, quick, inexpensive, commonly measured as part of routine liver function panels, and 
do not require a fasting state prior to venepuncture; they have the potential to be used in the identification 
of individuals at high risk of these adverse cardiovascular outcomes and in developing treatment methods. 
However, additional research is needed to help discover the mechanistic pathways of GGT in the 
pathogenesis of cardiovascular outcomes and larger studies are needed to confirm these findings. 
 
Strengths and limitations 
The notable strengths include a large sample that was selected to be a nationally representative population-
based sample of middle-aged men, was well characterised, involved high response and there were no 
losses during follow-up, reducing the risk of selection bias. Participants have been prospectively 
monitored using established databases for hospital admissions, supplemented with reliable data on a 
comprehensive panel of lifestyle and biological markers, including medication for hypertension and 
dyslipidaemia, to allow adequate adjustment for potential confounding; enabling reliable and independent 
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assessments of the associations. The mean follow-up period was sufficiently long to ascertain the risk for 
the various endpoints in the general population. Repeat measurements of GGT made within the same 
individuals over time were available, enabling correction for within-person variability. Several sensitivity 
analyses were conducted to ensure the robustness of our results. To put our GGT-HF results into context, 
we conducted a meta-analysis of five studies (including the present study) and demonstrated the reliability 
of our cohort analyses. The limitations of the present study also deserve mention. We were unable to 
assess the differential impact of GGT on risk of HF with preserved versus reduced ejection fractions, 
because there were no data on ventricular function post-HF development. There was no detailed 
information on whether cardiac arrhythmic events were paroxysmal (or treated by cardioversion) because 
arrhythmias were based on hospitalisation data. However, we detected the clinically most important 
arrhythmic events. There is a possibility that very short events of VAs and AF might have might have 
been missed without continuous heart rhythm monitoring systems in place. In the KIHD study, majority of 
sudden cardiac deaths (SCDs) that occurred during follow-up, occurred out-of-hospital (~80%)13; 
therefore it was not possible to detect all cases of VAs, given that SCD is generally considered to be a 
complication of ventricular fibrillation/tachycardia. In addition, ascertainment of arrhythmic events relied 
a lot on hospitalisation discharge codes, potentially missing cases that were asymptomatic. However, the 
validity of this approach for epidemiologic studies of this nature has been demonstrated to be adequate.32, 
33 Though a comprehensive panel of confounders was taken into account to ensure the validity of our 
results, potential residual confounding due to other unmeasured confounders (such as antioxidants, and 
other medications such as phenytoin or barbiturates that affect baseline levels of GGT) cannot be entirely 
ruled out. Measurements of other liver function enzymes such as the aminotransferases, were not made in 
the KIHD study, preventing comparison of the separate and joint associations of different liver function 
enzymes with the outcomes assessed. The study included only middle-aged Finnish men from eastern 
Finland and cannot necessarily be extrapolated to the young, women and other populations. However, the 
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pooled analyses for the GGT-HF and GGT-AF associations involved studies conducted in both men and 
women.  
 
Conclusions 
GGT activity is positively and log-linearly associated with future risk of HF, VAs, and AF. Further 
research is needed to assess the causal relevance of these findings. 
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Figure 1. Hazard ratios for heart failure, ventricular arrhythmias, and atrial fibrillation, by quartiles of 
baseline values of loge GGT 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent coronary 
heart disease, smoking status, history of diabetes, left ventricular hypertrophy, and use of medications 
(antihypertensive agents and lipid-lowering drugs); GGT, gamma-glutamyltransferase; the mean GGT 
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value (U/L) was 12.1 for the lowest quartile; 17.9 for the second quartile; 25.5 for the third quartile; and 
44.3 for the top quartile. 
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Figure 2. Relative risks for heart failure per 1 SD higher baseline and usual distribution of GGT values in 
published prospective studies 
 
Study acronyms are provided in Supplementary Material 7; A, relative risks per 1 standard deviation 
(SD) higher baseline GGT values; B, relative risks per 1 SD higher usual GGT values; Size of data 
markers are proportional to the inverse of the variance of the relative risk; CI, confidence interval (bars); 
GGT, gamma-glutamyltransferase; HF, heart failure 
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Table 1. Baseline characteristics and cross-sectional correlates of gamma-glutamyltransferase 
  
Mean (SD) or % 
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in GGT 
values per 1 SD higher or compared to 
reference category of correlate‡ 
Loge GGT (U/L) 3.11 (0.63)   
    
Questionnaire/Prevalent conditions    
Age at survey (yrs) 52.6 (5.0) -0.03 (-0.08, 0.02) -2% (-5, 1) 
Alcohol consumption (g/week) 76.1 (140.2) 0.27 (0.23, 0.31)*** 19% (15, 22)*** 
History of diabetes    
    No 95.4 - Ref 
    Yes 4.6 - 47% (28, 69)*** 
Smoking status    
    Other 67.6 - Ref 
    Current 32.4 - 11% (4, 18)** 
Left ventricular hypertrophy    
    No 98.9 - Ref 
    Yes 1.1 - -4% (-28, 28) 
History of hypertension    
    No 71.0 - Ref 
    Yes 29.0 - 27% (20, 36)*** 
History of CHD    
    No 78.1 - Ref 
    Yes 21.9 - 17% (9, 25)*** 
Use of anti-hypertensives    
    No 81.7 - Ref 
    Yes 18.3 - 24% (15, 34)*** 
Medication for dyslipidemia    
    No 99.4 - Ref 
    Yes 0.6 - 25% (-14, 81) 
    
Physical measurements    
BMI (kg/m2) 26.8 (3.5) 0.34 (0.30, 0.38)*** 24% (21, 27)*** 
SBP (mmHg) 133.9 (16.6) 0.21 (0.17, 0.26)*** 14% (11, 18)*** 
DBP (mmHg) 89.0 (10.5) 0.25 (0.21, 0.30)*** 17% (14, 21)*** 
Resting heart rate (bpm) 62.5 (10.7) 0.14 (0.10, 0.19)*** 9% (6, 13)*** 
    
Lipid markers    
Total cholesterol (mmol/l) 5.93 (1.10) 0.10 (0.05, 0.14)*** 6% (3, 9)*** 
HDL-C (mmol/l) 1.29 (0.30) -0.04 (-0.09, 0.01) -2% (-5, 0) 
Loge triglycerides (mmol/l) 0.09 (0.50) 0.26 (0.21, 0.30)*** 18% (14, 21)*** 
    
Metabolic, inflammatory, and renal 
markers 
   
Fasting plasma glucose (mmol/l) 5.33 (1.21) 0.21 (0.16, 0.25)*** 14% (11, 17)*** 
Serum creatinine (µmol/1) 89.4 (22.5) 0.00 (-0.04, 0.05) 0% (-3, 3) 
Loge C-reactive protein (mg/l) 0.29 (0.96) 0.27 (0.22, 0.31)*** 18% (15, 21)*** 
Estimated GFR (ml/min/1.73 m2) 87.7 (17.5) -0.01 (-0.05, 0.04) -0% (-3, 3) 
 
BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; GGT, gamma-
glutamyltransferase; SD, standard deviation; SBP, systolic blood pressure; ‡Percentage change in GGT values per 1-SD increase in the row 
variable (or for categorical variables, the percentage difference in mean GGT values for the category versus the reference) adjusted for age; 
asterisks indicate the level of statistical significance: *P<0.05, **P<0.01, ***P<0.001 
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Table 2. Associations of baseline and usual gamma-glutamyltransferase values with heart failure, ventricular arrhythmias, and atrial 
fibrillation 
 
Models Heart failure  Ventricular arrhythmias  Atrial fibrillation  
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
 1,780 participants and 222 cases  1,780 participants and 56 cases  1,780 participants and 336 cases  
   Baseline GGT    
Model 1 1.45 (1.28 to 1.67) < 0.001 1.48 (1.16 to 1.90) 0.002 1.15 (1.03 to 1.29) 0.011 
Model 2 1.25 (1.07 to 1.45) 0.004 1.37 (1.04 to 1.80) 0.026 1.04 (0.92 to 1.18) 0.522 
Model 3 1.26 (1.07 to 1.47) 0.004 1.30 (0.98 to 1.75) 0.068 1.05 (0.92 to 1.19) 0.502 
Model 4 1.24 (1.05 to 1.45) 0.009 1.31 (0.98 to 1.76) 0.069 1.06 (0.93 to 1.21) 0.412 
Model 5 1.25 (1.07 to 1.46) 0.006 1.32 (0.99 to 1.77) 0.062 1.06 (0.93 to 1.21) 0.405 
   Usual GGT    
Model 1 1.74 (1.43 to 2.12) < 0.001 1.78 (1.24 to 2.56) 0.002 1.24 (1.05 to 1.46) 0.011 
Model 2 1.38 (1.11 to 1.73) 0.004 1.58 (1.06 to 2.37) 0.026 1.06 (0.88 to 1.27) 0.522 
Model 3 1.40 (1.11 to 1.77) 0.004 1.49 (0.97 to 2.28) 0.068 1.07 (0.89 to 1.30) 0.502 
Model 4 1.36 (1.08 to 1.72) 0.009 1.49 (0.97 to 2.30) 0.069 1.09 (0.90 to 1.32) 0.412 
Model 5 1.39 (1.10 to 1.75) 0.006 1.51 (0.98 to 2.32) 0.062 1.09 (0.90 to 1.32) 0.405 
 
GGT, gamma-glutamyltransferase; hazard ratios are reported per 1 standard deviation increase in loge GGT levels; 1 standard deviation higher loge GGT was approximately 
equivalent to two-fold higher GGT values. 
Model 1: Adjusted for age 
Model 2: Model 1 plus BMI, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes, left ventricular hypertrophy, and use of medications 
(antihypertensive agents and lipid-lowering drugs) 
Model 3: Model 2 plus alcohol consumption, resting heart rate, triglycerides, total cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate 
Model 4: Model 3 plus C-reactive protein 
Model 5: Model 4 plus incident coronary heart disease as a time-dependent covariate 
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Supplementary Material 1: Study population, ascertainment of outcomes, and risk factor assessment 
 
Study population 
The study population consisted of a representative sample of men living in the city of Kuopio and its 
surrounding rural communities in eastern Finland. Subjects were participants in the Kuopio Ischaemic Heart 
Disease (KIHD) risk factor study, a longitudinal population-based study designed to investigate risk factors for 
CVD, atherosclerosis and related outcomes.1 Participants were 42-61 years of age during baseline examinations 
performed between March 1984 and December 1989. Of 3,433 potentially randomly eligible and randomly 
selected men, 2,682 (78%) volunteered to participate; 186 did not respond to the invitation and 367 declined to 
give informed consent. Men with a prevalent history of HF, cardiac arrhythmias, or liver disease were excluded 
(n=198). The final cohort for the present analysis included 1,780 men with non-missing information on serum 
GGT and covariates. The KIHD study complies with the Declaration of Helsinki and the Research Ethics 
Committee of the University of Eastern Finland approved the study, and each participant gave written informed 
consent. 
 
Ascertainment of outcomes 
All outcomes (HF, VAs, and AF) that occurred from study enrollment through 2012 were included. There were 
no losses to follow-up. In the KIHD study, participants are under continuous surveillance for the development of 
new CVD events, including new incident HF, VAs, and AF events.2 The sources of information on outcomes 
were based on a comprehensive review of hospital records and discharge diagnoses, inpatient physician claims 
data, study ECGs, and medico-legal reports. The diagnostic classification of HF cases was coded according to 
the ICD-10 codes (I50.0-I50.9, I11, I42.0-I42.9). ). The diagnosis of HF was based on diagnostic guidelines of 
the European Society of Cardiology3 and which included criteria such as symptoms, signs, laboratory 
investigations including the determination of natriuretic peptides, chest radiography results, echocardiography as 
well as electrocardiographic findings. The diagnostic classification of VAs was coded according to ICD-9 codes 
(427.41) or ICD-10 codes (I47.2, I49.0) codes. The definition of non-sustained or sustained ventricular 
tachycardia and/or ventricular fibrillation was based on electrocardiography.4 The diagnostic classification of 
AF cases was coded according to ICD-10 codes (I48.0-I48.9).5 Documents were cross-checked in detail by two 
physicians. The Independent Events Committee, masked to clinical data, performed classification of outcomes. 
 
Measurement of risk factors 
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Collection of blood specimens and the measurement of serum lipids, lipoproteins and glucose have been 
described previously.6 Blood samples were taken between 08:00 and 10:00 hours. In addition to fasting, 
participants were instructed to abstain from drinking alcohol for at least 3 days and from smoking for at least 12 
h prior to assessment. The serum samples were stored frozen at -80 °C for 0.2-2.5 years. Fasting plasma glucose 
(FPG) was measured by the glucose dehydrogenase method (Merck, Darmstadt, Germany). Serum GGT activity 
was measured using the kinetic method (Thermo Fisher Scientific, Vantaa, Finland). Serial measurements of 
GGT were performed 4 years and 11 years apart during a 22 year period in a random subset of participants. C-
reactive protein (CRP) was measured with an immunometric assay (Immulite High Sensitivity C-Reactive 
Protein Assay; DPC, Los Angeles, CA, USA). Smoking, alcohol consumption and blood pressure were assessed 
as described previously.6 Body mass index (BMI) was computed as the ratio of weight in kilograms to the 
square of height in metres. Standard resting 12-lead ECG was also recorded. The ECG criterion for left 
ventricular hypertrophy (LVH) was based on either the Sokolow-Lyon or Romhilt-Estes point score.7-10 
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Supplementary Material 2: Systematic review and meta-analysis methodology 
 
 
A systematic review was conducted using a predefined protocol and in accordance with the PRISMA and 
MOOSE guidelines1, 2 (Supplementary Materials 3-4). Prospective (cohort or nested case-control) studies of 
the association between GGT and incident HF that were published up to November 2015 were sought using 
computer-based databases (MEDLINE, EMBASE, and Science Citation Index). We crossed the term ‘gamma-
glutamyltransferase’ (and similar) with “heart failure”, “left ventricular dysfunction” (and similar terms) without 
any language restrictions. Further details on the search strategy are presented in Supplementary Material 5. 
Reference lists of the retrieved articles were searched for additional articles. Studies were eligible for inclusion 
if they had at least one year of follow-up. The relative risk (RR) with 95% confidence intervals (CIs) was used 
as the common measure of association across studies.  To enable a consistent approach to the meta-analysis and 
enhance consistency, reported study-specific RRs were transformed to per 1SD change in baseline GGT values 
using standard statistical methods 3, 4 which have been described in detail previously.5, 6 Briefly, log risk 
estimates were transformed assuming a normal distribution (or that a transformation of the explanatory variable 
for which the risk ratio is based was normally distributed). The log risk ratio for a 1 SD change being equivalent 
to the log risk ratio for a comparison of extreme thirds divided by 2.18 (equivalently, as the log risk ratio for a 
comparison of extreme quarters divided by 2.54 or as the log risk ratio for a comparison of extreme quintiles 
divided by 2.80). Standard errors of the log risk estimates were calculated using published confidence limits and 
were standardized in the same way. Associations of usual levels of GGT and HF were estimated using the 
correction factor derived from the KIHD Study. The summary RR (including the estimate from the present 
study) was calculated using random effects meta-analysis (subsidiary analyses used a fixed effect meta-
analysis). Statistical heterogeneity across studies was quantified using standard chi-square tests and the I2 
statistic.7   
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Supplementary Material 3: PRISMA 2009 check-list 
 
Section/topic 
Item 
No Checklist item 
Reported on 
page No 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both 1 
Abstract 
Structured summary 2 Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, 
interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review 
registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study 
design (PICOS) 
Methods 
Methods 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information 
including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication 
status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated Supplementary 
Material 5 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-
analysis) 
Methods 
Data collection process 10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis 
Not applicable 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for 
each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) Not applicable 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre- Not applicable 
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Section/topic 
Item 
No Checklist item 
Reported on 
page No 
specified 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with 
a flow diagram 
Supplementary 
Material 8 
Study characteristics 18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations Supplementary 
Material 9 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Not applicable 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect 
estimates and confidence intervals, ideally with a forest plot 
Figure 3 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Figure 3 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16) Not applicable 
Discussion 
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as 
health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, 
reporting bias) 
Discussion 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research Discussion 
Funding 
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic 
review 
None 
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Supplementary Material 4: MOOSE checklist  
 
Baseline and long-term gamma-glutamyltransferase and risk of heart failure and 
cardiac arrhythmias: prospective study and meta-analysis 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
√ Problem definition Elevated baseline circulating gamma-glutamyltransferase (GGT) has 
been demonstrated to be associated with risk of incident heart failure 
(HF), but the precise nature and magnitude of the association is 
uncertain 
√ Hypothesis statement There is a linear and positive relationship between GGT and HF risk 
√ Description of study outcomes Heart failure 
√ Type of exposure  Serum measurements of GGT 
√ Type of study designs used Prospective (cohort, case-cohort or “nested case control”) population-
based studies 
√ Study population Approximately general populations (i.e., did not select participants on 
the basis of confirmed pre-existing medical conditions such as 
hypertension, cardiovascular disease, liver disease, or chronic kidney 
disease at baseline).  
Reporting of search strategy should 
include 
 
√ Qualifications of searchers Setor Kunutsor, MD PhD; Hassan Khan, MD PhD 
√ Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE, EMBASE, Web of 
Science to November 2015.  
Search strategy: 
1 (Gamma glutamyltransferase”[MeSH] OR "gamma 
glutamyltransferase"[All Fields]) 
2 ("Heart failure"[MeSH] OR "heart pressure"[All Fields]) 
3 ("humans"[MeSH Terms]) 
4 (1 AND 2 AND 3) 
 
√ Databases and registries searched MEDLINE, EMBASE, and Web of Science 
√ Search software used, name and 
version, including special features 
Ovid was used to search EMBASE 
Reference Manager used to manage references  
√ Use of hand searching We searched bibliographies of retrieved papers  
√ List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
√ Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
√ Method of handling abstracts and 
unpublished studies 
None found 
√ Description of any contact with 
authors 
None 
Reporting of methods should include  
√ Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
√ Rationale for the selection and 
coding of data 
Data extracted from each of the studies were relevant to the 
population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
√ Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels. 
√ Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
Not applicable 
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on possible predictors of study results 
√ Assessment of heterogeneity Heterogeneity of the studies was explored with I2 statistic that 
provides the relative amount of variance of the summary effect due to 
the between-study heterogeneity. 
√ Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses and sensitivity analyses are 
detailed in the methods. We performed random effects meta-analysis 
(with a fixed effects model as a subsidiary analysis) with Stata 13. 
√ Provision of appropriate tables and 
graphics 
Table 1 and Figure 3 
Reporting of results should include  
√ Graph summarizing individual study 
estimates and overall estimate 
Figure 3 
√ Table giving descriptive information 
for each study included 
Supplementary Material 9 
√ Results of sensitivity testing 
 
Sensitivity analysis was conducted to assess the influence of each 
individual study by omitting one study at a time and calculating a 
pooled estimate for the remainder of the studies. Results section 
√ Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates, 
I2 values and results of sensitivity analyses 
Reporting of discussion should include  
√ Quantitative assessment of bias Not applicable 
 
√ Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
√ Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
√ Consideration of alternative 
explanations for observed results 
Discussed in the context of the results. 
√ Generalization of the conclusions Discussed in the context of the results. 
√ Guidelines for future research Assessment of the causal relevance of GGT to risk of HF 
√ Disclosure of funding source No separate funding was necessary for the undertaking of this 
systematic review. 
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Supplementary Material 5: Literature search strategy 
 
Relevant studies, published before November 29, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and the Science 
Citation Index databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals and 
by correspondence with study investigators. The computer-based searches combined search terms 
related to gamma-glutamyltransferase and hypertension without language restriction. 
 
(i) MEDLINE strategy to identify relevant exposures: 
(“Gamma glutamyltransferase”[MeSH] OR "gamma glutamyltransferase"[All Fields] OR "Gamma 
glutamyltranspeptidase"[MeSH] OR "gamma glutamyltranspeptidase"[All Fields]) 
 
(ii) MEDLINE strategy to identify relevant outcomes: 
("Heart failure"[MeSH] OR “heart failure”[All Fields] OR "Ventricular dysfunction"[MeSH] OR 
“ventricular dysfunction”[All Fields])  
 
(iii) MEDLINE strategy to identify relevant population: 
("humans"[MeSH Terms]) 
 
Parts i, ii and iii were combined using ‘AND’ to search MEDLINE. Each part was specifically 
translated for searching alternative databases. 
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Supplementary Material 6: Hazard ratios for heart failure, ventricular arrhythmias, and atrial 
fibrillation using multivariate-adjusted fractional polynomials 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent 
coronary heart disease, smoking status, history of diabetes, left ventricular hypertrophy, and use 
of medications (antihypertensive agents and lipid-lowering drugs); GGT, gamma 
glutamyltransferase 
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Supplementary Material 7: Hazard ratios for baseline and usual loge GGT values and heart 
failure risk by several participant level characteristics 
 
Age at survey (years)
< 54.4
≥ 54.4
Body mass index (kg/m2)
< 26.4
≥ 26.4
SBP (mmHg)
< 131.8
≥ 131.8
C-reactive protein (mg/l)
< 1.23
≥ 1.23
History of diabetes
No
Yes
Smoking status
Non-smokers
Current smokers
History of hypertension
No
Yes
History of CHD
No
Yes
Left ventricular hypertrophy
No
Yes
Subgroup
1032
748
890
890
892
888
895
885
1698
82
1203
577
1263
517
1389
391
1761
19
No of 
participants
105
117
79
143
84
138
89
133
202
20
154
68
125
97
143
79
214
8
No. of HF
events
1.06 (0.85, 1.31)
1.34 (1.11, 1.63)
1.31 (1.02, 1.68)
1.26 (1.05, 1.50)
1.38 (1.09, 1.74)
1.17 (0.97, 1.42)
1.10 (0.86, 1.42)
1.29 (1.07, 1.54)
1.23 (1.05, 1.44)
1.39 (0.93, 2.08)
1.31 (1.10, 1.55)
1.11 (0.85, 1.45)
1.26 (1.04, 1.52)
1.23 (0.98, 1.54)
1.15 (0.95, 1.38)
1.42 (1.14, 1.78)
1.25 (1.07, 1.45)
1.21 (0.49, 2.99)
HR (95% CI)
1.5 .75 1.5 2.5 5
HR (95% CI) per 1 SD higher baseline log
e
GGT
1.09 (0.79, 1.50)
1.54 (1.16, 2.04)
1.49 (1.03, 2.15)
1.40 (1.08, 1.83)
1.61 (1.14, 2.26)
1.26 (0.95, 1.67)
1.15 (0.80, 1.66)
1.45 (1.11, 1.90)
1.36 (1.07, 1.71)
1.62 (0.90, 2.93)
1.49 (1.16, 1.91)
1.17 (0.79, 1.73)
1.40 (1.06, 1.86)
1.36 (0.97, 1.89)
1.23 (0.93, 1.62)
1.67 (1.21, 2.32)
1.39 (1.11, 1.74)
1.32 (0.35, 5.00)
HR (95% CI)
.088
.784
.278
.327
.563
.291
.863
.134
.945
P-value*
1.25 .5 .75 1.5 2.5 5
HR (95% CI) per 1 SD higher usual log
e
GGT
(A) (B)
 
Hazard ratios (HRs) were adjusted for age, body mass index, systolic blood pressure, prevalent coronary heart 
disease, smoking status, history of diabetes, left ventricular hypertrophy, and use of medications (antihypertensive 
agents and lipid-lowering drugs); A, HRs per 1 standard deviation (SD) higher baseline loge GGT values; B, HRs 
per 1 SD higher usual loge GGT values; CHD, coronary heart disease; CI, confidence interval; GGT, gamma-
glutamyltransferase; HF, heart failure; SBP, systolic blood pressure; *, P-value for interaction 
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Supplementary Material 8: Selection of studies included in the meta-analysis 
 
42 Potentially relevant citations identified
From MEDLINE, EMBASE, and Web of Science
37 excluded on the basis of 
title and/ or abstract
1 excluded on the basis of a 
review
4 articles plus current study
5 Full-text articles retrieved for more 
detailed evaluation
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Supplementary Material 9: Prospective studies of gamma-glutamyltransferase and incident heart failure 
 
Author, year of 
publication 
Study Location Population source Year of baseline survey Age range at 
baseline 
(yrs.) 
Male 
(%) 
Mean 
follow-up 
(yrs.) 
No. of 
cases 
No. of 
participants 
Covariates adjusted for 
Ruttmann, 2005 VHM&PP Austria Population register 1985-2001 >/=19 45.6 17 162 163,944 Age, BMI, SBP, cholesterol, TGs, glucose, 
smoking, work status, year of examination 
Dhingra, 2010 FHS 
Offspring 
USA FHS register 1948 44† 48.3 23.6 188 3,544 Age, sex, BMI, DM, smoking, SBP, treatment for 
hypertension, alcohol intake, total/HDL-
cholesterol ratio, valve disease, history of MI, 
AST, ALT, CRP 
Wannamethee, 2012 BRHS UK GP register 1978-1980 60-79 100.0 9 168 3,494 Age, BMI, smoking, social class, alcohol intake, 
prevalent stroke, DM, AF, LVH, 
antihypertensive drugs, FEV1, SBP, cholesterol, 
CRP, vWF, leptin, NT-proBNP, HOMA-IR, 
AST/ALT 
Wang, 2013 FINRISK Finland Population register 1982 / 1987 / 1992 / 1997 
/ 2002 
25-74 48.2 14.5 1,081 38,079 Age, study area, study year, smoking, education, 
alcohol consumption, PA, history of valvular 
disease, BMI, SBP, cholesterol at baseline, MI 
Current Study KIHD Finland Population register 1984-1989 42-61 100 22.0 222 1,780 Age, BMI, SBP, prevalent coronary heart 
disease, smoking status, history of diabetes, LVH, 
use of medications (antihypertensive agents and 
lipid-lowering drugs), alcohol consumption, 
resting heart rate, TGs, total cholesterol, HDL-
cholesterol, CRP, and incident CHD as a time-
varying covariate 
 
 Total       1,821 210,841  
 
*Range of follow-up. †Mean age at baseline 
Abbreviations: AF, atrial fibrillation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BRHS, British Regional Heart Study; CHD, coronary heart disease; CRP, C-
reactive protein; DM, diabetes mellitus; FEV1, (forced expiratory volume in 1 second; FHS, Framingham Heart Study; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment for insulin 
resistance; KIHD, Kuopio Ischaemic Heart Disease Study; LVH, left ventricular hypertrophy; MI, myocardial infarction; NT-proBNP, N terminal pro brain natriuretic peptide; PA, physical activity; SBP, 
systolic blood pressure; TG, triglyceride; VHM&PP, The Vorarlberg Health Monitoring and Promotion Program; vWF, von Willebrand factor 
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Supplementary Material 10: Hazard ratios for baseline and usual loge GGT values and ventricular 
arrhythmias risk by several participant level characteristics 
Age at survey (years)
< 54.4
≥ 54.4
Body mass index (kg/m2)
< 26.4
≥ 26.4
SBP (mmHg)
< 131.8
≥ 131.8
C-reactive protein (mg/l)
< 1.23
≥ 1.23
History of diabetes
No
Yes
Smoking status
Non-smokers
Current smokers
History of hypertension
No
Yes
History of CHD
No
Yes
Subgroup
1,032
748
890
890
892
888
895
885
1,698
82
1,203
577
1,263
517
1,389
391
No of 
participants
33
23
25
31
20
36
27
29
51
5
39
17
35
21
41
15
No. of VAs
1.16 (0.80, 1.69)
1.60 (1.11, 2.32)
1.23 (0.80, 1.88)
1.38 (0.97, 1.96)
1.47 (0.93, 2.32)
1.33 (0.96, 1.84)
1.51 (0.99, 2.29)
1.27 (0.89, 1.81)
1.43 (1.08, 1.90)
0.88 (0.36, 2.14)
1.38 (1.00, 1.91)
1.34 (0.85, 2.11)
1.35 (0.99, 1.86)
1.38 (0.87, 2.19)
1.41 (1.03, 1.93)
1.26 (0.76, 2.09)
HR (95% CI)
1.25 .5 .75 1.5 2.5
HR (95% CI) per 1 SD higher baseline log
e
GGT
1.24 (0.72, 2.16)
2.00 (1.16, 3.43)
1.36 (0.72, 2.54)
1.61 (0.96, 2.69)
1.76 (0.90, 3.45)
1.52 (0.94, 2.45)
1.83 (0.99, 3.40)
1.42 (0.84, 2.40)
1.69 (1.12, 2.56)
0.83 (0.22, 3.07)
1.61 (1.00, 2.58)
1.54 (0.79, 3.00)
1.55 (0.98, 2.47)
1.61 (0.81, 3.17)
1.66 (1.04, 2.63)
1.40 (0.67, 2.96)
HR (95% CI)
.214
.676
.724
.532
.301
.917
.939
.701
P-value*
1.25 .5 .75 1.5 2.5 5
HR (95% CI) per 1 SD higher usual log
e
GGT
(A) (B)
 
Hazard ratios were adjusted for age, body mass index, systolic blood pressure, prevalent coronary heart disease, smoking status, 
history of diabetes, left ventricular hypertrophy, and use of medications (antihypertensive agents and lipid-lowering drugs); A, 
HRs per 1 standard deviation (SD) higher baseline loge GGT values; B, HRs per 1 SD higher usual loge GGT values; CHD, 
coronary heart disease; CI, confidence interval; GGT, gamma-glutamyltransferase; HR, hazard ratio; SD, standard deviation; 
VAs, ventricular arrhythmias; *, P-value for interaction 
 
 
 
 
 
